VICURON PHARMACEUTICALS
Vicuron Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products for the treatment of seriously ill patients. Its lead products are in Phase III clinical trials and include anidulafungin, a novel antifungal agent; and dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections. The company�s products also include ramoplanin, which is an oral nonabsorbable form of ant... ibiotic that selectively inhibits Gram-positive bacteria, and various types of vancomycin-resistant enterococci and Clostridia. In addition, it provides VIC-Acne, a topical antibiotic cream that is in Phase I clinical trail. Vicuron Pharmaceuticals has research collaboration agreements with Novartis Pharma AG to develop deformylase inhibitors as new antibacterial agents and to provide target-based screens; and Pfizer, Inc. to discover second and third generation oxazolidinones. The company was incorporated as Versicor, Inc. in 1995 and changed its name to Vicuron Pharmaceuticals, Inc. in 2003. Vicuron Pharmaceuticals is headquartered in King of Prussia, Pennsylvania. Vicuron Pharmaceuticals Inc. is a former subsidiary of Pfizer Inc.
VICURON PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1995-01-01
Address:
King Of Prussia, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Similar Organizations
Abmaxis, Inc.
Abmaxis, Inc., a biopharmaceutical company, engages in the discovery, optimization, and development of monoclonal antibody (MAb) products.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
BoneCare International
Bone Care International, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization.
Heritage Pharmaceuticals
Heritage Pharmaceuticals a generic pharmaceutical company, engages in the acquisition, development, marketing, licensing, sale.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Novel Laboratories
Novel Laboratories a pharmaceutical company, engages in the research, development, and manufacture of generic and branded products.
QuatRx Pharmaceuticals
QuatRx Pharmaceuticals Company, a biopharmaceutical company, engages in discovering, licensing, developing, and commercializing compounds
Current Advisors List
Founder
More informations about "Vicuron Pharmaceuticals"
Vicuron Pharmaceuticals - Crunchbase Company Profile & Funding
Vicuron Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products for the treatment of …See details»
Vicuron Pharmaceuticals Inc - Company Profile and News
Vicuron Pharmaceuticals Inc. provides biopharmaceutical products. The Company discovers, develops, manufactures, and commercializes vital medicine for seriously ill patients for novel …See details»
PFIZER TO BUY VICURON | C&EN Global Enterprise - ACS …
Jun 20, 2005 · PFIZER HAS AGREED TO BUY Vicuron Pharmaceuticals, a biopharmaceutical company specializing in anti-infection therapies for hospital- and community-acquired …See details»
Pfizer Completes Acquisition of Vicuron Pharmaceuticals
Sep 16, 2005 · Through the transaction, Pfizer has acquired two new product candidates currently under review at the U.S. Food and Drug Administration (FDA): anidulafungin for fungal …See details»
Vicuron Pharmaceuticals - Products, Competitors, Financials, …
Vicuron Pharmaceuticals is a pharmaceutical company with a focus on developing anti-infective products for the healthcare sector. The company's main offerings include proprietary injectable …See details»
Pfizer acquires Vicuron in $1.9B deal - Fierce Biotech
Jun 15, 2005 · Biopharma giant Pfizer is paying $1.9 billion to buy Vicuron Pharmaceuticals, a King of Prussia, Pennsylvania-based drug developer with two products under FDA review. The …See details»
Durata Therapeutics Acquires Pfizer’s Subsidiary that Develops …
Dec 21, 2009 · Durata Therapeutics is taking over a Pfizer subsidiary focused on antibiotics called Vicuron Pharmaceuticals. It gains late-stage dalbavancin and two preclinical programs. Pfizer …See details»
Press Release - SEC.gov
NEW YORK and KING OF PRUSSIA, Pa., June 16 — Pfizer Inc. (NYSE: PFE) and Vicuron Pharmaceuticals, Inc. (Nasdaq: MICU, Nuovo Mercato) today announced that they have …See details»
Organization | Vicuron Pharmaceuticals
Vicuron Pharmaceuticals Report issue For profit Phase 2 Phase 3 Founded: King of Prussia PA United States (1995)See details»
Pfizer to buy Vicuron for $1.9 billion - MarketWatch
Jun 16, 2005 · BOSTON (MarketWatch) -- U.S. pharmaceutical giant Pfizer Inc. said Thursday it has agreed to acquire Vicuron Pharmaceuticals Inc. for $1.9 billion in a move that will help …See details»
VICURON PHARMACEUTICALS INC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VICURON PHARMACEUTICALS INC of King OF Prussia, PA. Get the latest business insights from Dun …See details»
Vicuron Pharmaceuticals - PitchBook
Developer of anti-fungal and antibiotic agent. The company's main product includes anidulafungin, novel anti-fungal agent, dalbavancin and novel antibiotic for the treatment of serious Gram …See details»
Pfizer to acquire Vicuron for $1.9 billion - NBC News
Jun 16, 2005 · Pfizer Inc., the world’s biggest drug maker, agreed on Thursday to acquire Vicuron Pharmaceuticals Inc., a biopharmaceutical company focused on the development of new anti …See details»
Pfizer, Vicuron in $1.9 billion merger - outsourcing-pharma.com
Jun 16, 2005 · Pfizer has struck a deal to buy Vicuron Pharmaceuticals, for $1.9 billion (€1.6 billion) in cash, in a move that places the drug company further into the realms of anti-infective …See details»
Durata Acquires Vicuron From Pfizer - Pharmaceutical Business …
Durata Therapeutics (Durata) has acquired Vicuron Pharmaceuticals (Vicuron) from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created to pursue late-stage …See details»
Newly formed Durata Therapeutics acquires Vicuron …
Dec 21, 2009 · Durata Therapeutics, Inc., a newly formed biopharmaceutical company, announced that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata was …See details»
Pfizer Receives Approvable Letter from FDA for Dalbavancin
Dec 21, 2007 · Dalbavancin was acquired by Pfizer in September 2005 as part of its acquisition of Vicuron Pharmaceuticals, Inc. Pfizer has a long history of developing new medicines for …See details»
Vicuron Sells Shares, Gets $70.8M For Lead Products
Oct 1, 2004 · Vicuron plans to establish its own direct sales force in certain markets for anidulafungin and dalbavancin, and it also has a strategy to collaborate with pharmaceutical …See details»
Vicuron Pharmaceuticals - Contacts, Employees, Board Members, …
We're working on getting contact data for Vicuron Pharmaceuticals. Find more contact data in Search! Vicuron Pharmaceuticals has 1 board member or advisor, Mark Leschly.See details»
Vicuron Pharmaceuticals Announces Data At ICAAC Supporting
KING OF PRUSSIA, Pa., Nov. 1 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that research generated from its internal discovery …See details»